To explore the role of insulin-like growth factor 1 (IGF-1) in the development of thyroid associated ophthalmopathy

To determine the correlation between clinical activity scores of patients with thyroid associated ophthalmopathy (TAO) and their locally produced and / or systemically circulated insulin-like growth factor 1 (IGF-1): a single-centre case-controlled study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN34713784

Enrollment

Registered

2011-08-16

Start date

2010-01-03

Completion date

Unknown

Last updated

2017-06-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thyroid associated ophthalmopathy Eye Diseases Dysthyroid exophthalmos

Interventions

The IGF-1 in serum levels and IGF-1 concentration in culture media of orbital fibroblasts were determined by an Enzyme-linked immunosorbent assay (ELISA) kit. No follow up after the sample collection

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. TAO patients and healthy controls above 18-year old, either sex 2. Body mass index (BMI) (18.5-25 kg/m2)

Exclusion criteria

Exclusion criteria: Individuals with: 1. Non-thyroid autoimmune diseases 2. Asthma 3. Granulomatous disease 4. Sinusitis 5. Human immunodeficiency virus (HIV) infection 6. Pregnancy 7. Undercurrent illness

Design outcomes

Primary

Measure	Time frame
No correlation was found between levels of either total or free IGF-1 in serum with clinical activity score (CAS) of TAO patients, but the IGF-1 in culture medium of orbital fibroblast from TAO patients positively correlated with CAS.	—

Secondary

Measure	Time frame
The IGF-1 level in culture medium of orbital fibroblast, determined by a commercial enzyme linked immunosorbent assay ELISA kit, after 48hr in culture.	—

Countries

China

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026